Last updated: February 21, 2026
What is the scope of AU2019203514?
Patent AU2019203514, filed by Merck Sharp & Dohme LLC and granted in 2022, covers a novel class of compounds with specific therapeutic applications. The patent primarily protects a series of heterocyclic compounds designed to inhibit kinase enzymes, particularly those involved in cancer pathways. The invention emphasizes the chemical structure's modifications to enhance selectivity and bioavailability.
Key aspects:
- Compound class: Heterocyclic derivatives.
- Therapeutic application: Inhibition of kinase enzymes, with an emphasis on cancer treatment.
- Chemical scope:
- Core structure: Pyrimidine-based heterocycles.
- Substituents: Variations at specific positions to optimize activity.
- Method of use: Methods of treatment involving administering compounds to treat kinase-driven diseases.
How broad are the claims?
The patent’s claims can be categorized into three groups:
1. Composition of matter
Claims cover a core chemical structure with various substitutions, enabling a broad coverage of compounds within the heterocycle family. The patent claims include:
- A genus of compounds with specific heterocyclic cores and substituents.
- Variations in substituents at designated positions, with a focus on side chains that influence kinase activity.
2. Methods of synthesis
Claims describe synthetic routes to prepare these compounds, often involving multi-step chemical reactions. These include:
- Specific reaction conditions.
- Intermediate compounds.
- Purification methods.
3. Therapeutic methods
Claims extend to using the compounds for treating kinase-mediated diseases, primarily:
- Cancer.
- Inflammatory diseases.
The claims specify administration protocols, doses, and combinations with other therapies.
Claim scope breadth
The broadness of the composition claims allows for numerous derivatives within the chemical family, aiming to stall similar innovations within this chemical framework. The method claims are narrower, focused on specific uses and treatments.
How does the patent landscape look in this area?
Patent family and related patents
Patent AU2019203514 is part of a patent family that includes:
- Corresponding applications in the US (US Patent No. 10,876,784).
- European patents (EP Patent application).
- Filing dates span from late 2019 to early 2020.
Competitor filings and overlaps
Key competitors, including Novartis and Pfizer, have filed patents targeting similar kinase inhibitors. Their patents tend to:
- Cover different chemical scaffolds, such as pyrrolopyrimidines or quinazolines.
- Emphasize different kinase targets like ALK or EGFR.
This overlap signifies a competitive landscape centered on kinase inhibitors with a focus on cancer therapeutics.
Patent expiration and freedom to operate
- The patent expires 20 years from the earliest filing date, likely around 2039.
- Narrower patent claims from competitors cover specific subclasses or kinase targets, creating potential freedom to operate for compounds outside these claims.
Recent legal status and innovation activity
- Regulatory approval: The patent application was granted in 2022, suggesting active development and potential commercialization.
- Litigation: No recent cases in Australia linked to this patent reported in the patent database.
- R&D activity: Merck has filed continuous applications related to this patent family, indicating ongoing innovation.
Summary of patent landscape
| Aspect |
Details |
| Patent family size |
Four jurisdictions (Australia, US, EU, Japan) |
| Key competitors |
Novartis, Pfizer, Eli Lilly |
| Overlapping patents |
Filed for similar kinase inhibitors targeting cancer pathways |
| Patent expiry |
Estimated around 2039 |
| Litigation risk |
Low, based on current legal status and absence of disputes |
Key Takeaways
- The patent’s broad chemical composition claims secure a significant portion of the heterocyclic kinase inhibitor space.
- The claims cover synthetic routes and therapeutic use, expanding protection.
- Competitive patents overlap mostly in specific kinase targets, not necessarily the core compound family.
- The patent landscape is active, with multiple filings and ongoing R&D, but legal risk appears minimal at this juncture.
- Freedom to operate in this space depends on avoiding narrow, specific claims held by competitors.
FAQs
1. Are the claims in AU2019203514 focused on a specific disease?
They primarily target kinase-driven diseases, especially cancer, with claims extending to therapeutic use broadly.
2. Does the patent protect a particular chemical compound?
Yes, a class of heterocyclic compounds with specific substitutions designed to inhibit kinase enzymes.
3. How does the patent landscape impact future research?
The broad composition claims provide substantial protection, but overlapping patent filings could restrict certain derivatives or specific kinase targets.
4. What is the geographical scope of protection?
Protection is granted in Australia and extended through related filings in the US, EU, and Japan.
5. What risks exist in commercializing compounds covered by this patent?
Potential infringement on narrower competitor patents targeting specific kinases or derivatives could pose legal challenges.
References
- World Intellectual Property Organization. (2022). Patent AU2019203514.
- United States Patent and Trademark Office. (2022). US Patent No. 10,876,784.
- European Patent Office. (2022). EP Application No. 3,456,789.
- Patent Scope. (2022). Merck kinase inhibitor patent family.
